All articles tagged with #alpha synuclein
Researchers identify the brain protein GPNMB, largely produced by microglia, as a driver of alpha-synuclein spread in Parkinson's disease. Monoclonal antibodies that block GPNMB halted this spread in neuronal models, and analysis of 1,675 brains linked higher GPNMB levels to more extensive pathology, suggesting a potential disease-modifying therapy—though human trials have not yet begun.
A study links a distinctive gut microbiome signature to Parkinson’s risk, even among people with a genetic predisposition but no symptoms, suggesting potential for early detection and possibly prevention or delay through dietary changes or microbiome-targeted therapies, though causality remains unclear and more research is needed.
A Baylor College of Medicine study suggests increasing cellular tubulin can steer Tau and alpha-synuclein away from harmful aggregates toward healthy microtubule activity, offering a potential therapeutic strategy for Alzheimer’s and Parkinson’s by boosting tubulin rather than blocking condensate formation.
A Mayo Clinic study finds misfolded alpha-synuclein linked to tau buildup that progresses up to 20 times faster in women with Alzheimer's brain changes, suggesting a sex-specific mechanism behind women's higher Alzheimer's risk and guiding targeted trials and diagnostics.
A Mayo Clinic study of 415 participants found that older women with Alzheimer's who tested positive for the Parkinson's-related protein alpha-synuclein accumulated tau about 20 times faster than men with the same abnormal protein, suggesting alpha-synuclein may accelerate Alzheimer's progression in women. The findings indicate sex-specific disease trajectories and potential biomarker-guided therapies, but replication is needed before changing treatment approaches.
A review of 100+ studies links microplastics and nanoplastics to brain pathways involved in Parkinson's disease, suggesting these pollutants can enter the body via ingestion, inhalation, or skin contact and reach the brain to promote alpha-synuclein clumps and neuroinflammation, as well as disrupt gut-brain communication and ferry metals; however, most evidence comes from animal/cell studies and human data are limited, so more research is needed alongside reducing plastic pollution and improving waste management.
A Mayo Clinic study finds that women with coexisting alpha-synuclein (Parkinson’s) and tau (Alzheimer’s) abnormalities experience tau accumulation and brain degeneration up to 20 times faster than those without the co-pathology, a sex-specific effect not seen in men, suggesting the need for gender-tailored screening and treatments.
CWRU researchers link alpha-synuclein to mitochondrial dysfunction in Parkinsons by binding to the ClpP enzyme; they designed a CS2 decoy to block this interaction, reducing inflammation and restoring function in cells and animal models, offering a potential root-cause therapy with human trials possible in about five years.
Scientists show that alpha-synuclein directly binds the ClpP enzyme, sabotaging mitochondria and fueling neuron loss in Parkinson's models; they created CS2, a decoy that blocks this interaction, restoring mitochondrial function, reducing inflammation, and improving movement and cognition in tissue and animal models, with plans to advance toward human trials.
Researchers have identified that alpha-synuclein binds to the mitochondrial enzyme ClpP, impairing energy production and accelerating neuron loss in Parkinson’s disease. They developed CS2, a decoy therapy that blocks this interaction and restores mitochondrial function, showing reduced inflammation and improved movement and cognition in human tissue, patient-derived neurons, and mouse models. The work points to a disease-modifying treatment targeting a root cause, with plans to advance toward human trials in the next five years.
Parkinson's disease is discussed as a neurodegenerative condition linked to misfolded alpha-synuclein, with early non-motor signs such as reduced sense of smell and REM sleep behavior disorder often appearing years before tremors; evidence suggests initiation in the nose or gut with brain-wide spread, while environmental factors like air pollution, pesticides, and solvents may raise risk and drive prevention efforts. The Parkinson's Progression Markers Initiative aims to detect the disease earlier with biomarkers (e.g., alpha-synuclein assays) to speed treatments, but no current therapy slows progression; emphasis on exercise and sleep as important, potentially protective, interventions.
A UCLA-led study links long-term chlorpyrifos exposure to about a 2.74-fold increase in Parkinson's disease risk, based on 829 PD cases and 824 controls using California pesticide-use data and residence/work addresses; animal models show dopamine neuron loss and alpha-synuclein buildup with autophagy disruption, which can be mitigated by stimulating autophagy, supporting a likely causal link while noting many factors influence PD and that chlorpyrifos use persists in the US.
Scientists in the UK have developed a peptide that stabilizes alpha-synuclein, a protein linked to Parkinson's and dementia, preventing harmful clumping in the brain. In animal models, this approach reduced protein buildup and improved movement, offering a promising avenue for future treatments of neurodegenerative diseases.
A new study suggests that alpha-synuclein oligomers may damage brain cells by forming dynamic pores in cell membranes, potentially contributing to Parkinson's disease progression, and offers new insights into the disease's mechanisms and potential treatments.
A study links fine particulate air pollution (PM2.5) to Lewy body dementia by showing that exposure triggers toxic alpha-synuclein protein clumps in the brain, increasing disease risk and suggesting pollution as a potential target for prevention and treatment.